Every SEC Form 3/4/5 on record for this filer (CIK 1730048) — 2 issuers, 122 transactions. Section-16 filings only: what they filed, not a biography, and titles are as filed on their latest form at each issuer.
| Ticker | Company | Role as filed | On file | Forms | Open-market net |
|---|---|---|---|---|---|
| ALKS | Alkermes plc. | EVP R&D, Chief Medical Officer | 2018-02-09 → 2026-06-01 | 53 | −$23M |
| ALBO | ALBIREO PHARMA, INC. | Director · lapsed | 2022-12-05 → 2023-03-02 | 3 | — |
| Ticker | Date | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| ALKS | 2026-06-01 | Sell | 9,000 | $41.67 | $375,030 | 77,389 |
| ALKS | 2026-05-01 | Sell | 9,000 | $33.40 | $300,600 | 81,389 |
| ALKS | 2026-04-01 | Sell | 9,000 | $35.51 | $319,590 | 85,389 |
| ALKS | 2026-03-02 | Sell | 9,000 | $29.72 | $267,480 | 89,389 |
1 of 2 issuers are covered and open a security page; the rest are on file here only.
